May 5, 2017 8:59am
Financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene and regenerative therapy's companies.
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!
By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
COMPANY | SYMBOL | NET INCOME | Q1/17 LOSS | Q1/17 LPS | Q1/17 CASH |
---|---|---|---|---|---|
Aduro Biotech, Inc. | ADRO | ||||
Applied Genetic Technologies | AGTC | ||||
Asterias Biotherapeutics | AST | ||||
Athersys, Inc. | ATHX | ||||
Adverum Biotechnologies, Inc. | ADVM | ||||
AxoGen, Inc. | AXGN | ||||
Bellicum Pharmaceuticals, Inc. | BLCM | ||||
BioLife Solutions, Inc. | BLFS | ||||
Biostage, Inc. | BSTG | ||||
BioTime, Inc. | BTX | ||||
bluebird bio | BLUE | ||||
Brainstorm Cell Therapeutics Inc. | BCLI | ||||
Caladrius Biosciences. | CLBS | ||||
Capricor | CAPR | ||||
Cellectis | CLLS | ||||
Cesca Therapeutics, Inc | KOOL | ||||
Cytori Therapeutics, Inc. | CYTX | ||||
Fate Therapeutics, Inc. | FATE | ||||
Fibrocell Science, Inc. | FCSC | ||||
Histogenics Corporation | HSGX | ||||
ImmunoCellular Therapeutics, Ltd. | IMUC | ||||
International Stem Cell | ISCO | ||||
Intrexon Corporation | XON | ||||
Juno Therapeutics, Inc. | JUNO | ||||
Kite Pharma, Inc. | KITE | ||||
Mesoblast Limited | MBLTY | ||||
MiMedx Group, Inc | MDXG | ||||
Neuralstem, Inc. | CUR | ||||
Northwest Biotherapeutics, Inc. | NWBO | ||||
Opexa Therapeutic, Inc. | OPXA | ||||
Organovo Holdings, Inc. | ONVO | ||||
Osiris Therapeutics, Inc. | OSIR | ||||
Pluristem Therapeutics, Inc. | PSTI | ||||
ReNeuron Group PLC | RENE.L | ||||
Regenxbio | RGNX | ||||
Sangamo Biosciences, Inc. | SGMO | ||||
Spark Therapeutics, Inc. | ONCE | ||||
Stemline Therapeutics, Inc. | STML | ||||
uniQure N.V. | QURE | ||||
Verastem, Inc. | VSTM | ||||
Vericel Corporation | VCEL | ||||
VistaGen Therapeutics, Inc. | VTGN |